Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L.
Ruf T, et al. Among authors: french le.
Eur J Cancer. 2024 Mar 27;203:114028. doi: 10.1016/j.ejca.2024.114028. Online ahead of print.
Eur J Cancer. 2024.
PMID: 38652976